Xanadu Bio
Cambridge, United States· Est.
Xanadu Bio leverages its PACE polymer platform to create safe, organ‑targeted mRNA delivery for oncology, immunology, and intranasal vaccines.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Xanadu Bio leverages its PACE polymer platform to create safe, organ‑targeted mRNA delivery for oncology, immunology, and intranasal vaccines.
OncologyImmunologyInfectious Disease
Technology Platform
PACE (poly(amine‑co‑ester)) polymer nanoparticles that are tunable, organ‑specific, and immune‑silent for efficient delivery of mRNA and other nucleic‑acid cargos.
Opportunities
Successful IND filing and early‑phase clinical data could unlock partnerships with major pharma seeking novel nucleic‑acid delivery platforms for oncology and vaccine programs.
Risk Factors
Pre‑clinical stage carries high technical and regulatory risk; scaling manufacturing and demonstrating safety in humans are critical hurdles.
Competitive Landscape
Xanadu competes with lipid nanoparticle and other polymer delivery companies, but its PACE platform’s organ‑targeting tunability and reduced immunogenicity offer a differentiated value proposition.